BACKGROUND: Minimal residual disease of the peritoneum is challenging for early cancer detection in gastric cancer (GC). Utility of PCR amplification of cancer-derived DNA has been considered feasible due to its molecular stability, however such markers have never been available in GC clinics. We recently discovered cancer-specific methylation of CDO1 gene in GC, and investigated the clinical potential to detect the minimal residual disease. METHODS: One hundred and two GC patients were investigated for peritoneal fluid cytology test (CY), and detection level of the promoter DNA methylation of CDO1 gene was assessed by quantitative methylation specific PCR (Q-MSP) in the sediments (DNA CY). RESULTS: (1) CY1 was pathologically confirmed in 8 cases, while DNA CY1 was detected in 18 cases. All 8 CY1 were DNA CY1. (2) DNA CY1 was recognized in 14.3, 25.0, 20.0, and 42.9%, in macroscopic Type II, small type III, large type III, and type IV, respectively, while it was not recognized in Type 0/I/V. (3) DNA CY1 was prognostic relevance in gastric cancer (p = 0.0004), and its significance was robust among Type III/IV gastric cancer (p = 0.006 for overall survival and p = 0.0006 for peritoneal recurrence free survival). (4) The peritoneal recurrence was hardly seen in GC patients with potent perioperative chemotherapy among those with DNA CY1. CONCLUSIONS: DNA CY1 detected by Q-MSP for CDO1 gene promoter DNA methylation has a great potential to detect minimal residual disease of the peritoneum in GC clinics as a novel DNA marker.
BACKGROUND: Minimal residual disease of the peritoneum is challenging for early cancer detection in gastric cancer (GC). Utility of PCR amplification of cancer-derived DNA has been considered feasible due to its molecular stability, however such markers have never been available in GC clinics. We recently discovered cancer-specific methylation of CDO1 gene in GC, and investigated the clinical potential to detect the minimal residual disease. METHODS: One hundred and two GC patients were investigated for peritoneal fluid cytology test (CY), and detection level of the promoter DNA methylation of CDO1 gene was assessed by quantitative methylation specific PCR (Q-MSP) in the sediments (DNA CY). RESULTS: (1) CY1 was pathologically confirmed in 8 cases, while DNA CY1 was detected in 18 cases. All 8 CY1 were DNA CY1. (2) DNA CY1 was recognized in 14.3, 25.0, 20.0, and 42.9%, in macroscopic Type II, small type III, large type III, and type IV, respectively, while it was not recognized in Type 0/I/V. (3) DNA CY1 was prognostic relevance in gastric cancer (p = 0.0004), and its significance was robust among Type III/IV gastric cancer (p = 0.006 for overall survival and p = 0.0006 for peritoneal recurrence free survival). (4) The peritoneal recurrence was hardly seen in GC patients with potent perioperative chemotherapy among those with DNA CY1. CONCLUSIONS: DNA CY1 detected by Q-MSP for CDO1 gene promoter DNA methylation has a great potential to detect minimal residual disease of the peritoneum in GC clinics as a novel DNA marker.
Entities:
Keywords:
Cysteine dioxygenase type 1 (CDO1); DNA diagnosis; DNA methylation; Gastric cancer; Peritoneal fluid cytology test
Authors: Andrew Feber; Manit Arya; Patricia de Winter; Muhammad Saqib; Raj Nigam; Peter R Malone; Wei Shen Tan; Simon Rodney; Matthias Lechner; Alex Freeman; Charles Jameson; Asif Muneer; Stephan Beck; John D Kelly Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: Keishi Yamashita; Sunil Upadhyay; Motonobu Osada; Mohammad O Hoque; Yan Xiao; Masaki Mori; Fumiaki Sato; Stephen J Meltzer; David Sidransky Journal: Cancer Cell Date: 2002-12 Impact factor: 31.743
Authors: Mariana Brait; Shizhang Ling; Jatin K Nagpal; Xiaofei Chang; Hannah Lui Park; Juna Lee; Jun Okamura; Keishi Yamashita; David Sidransky; Myoung Sook Kim Journal: PLoS One Date: 2012-09-27 Impact factor: 3.240
Authors: Hege Marie Vedeld; Kim Andresen; Ina Andrassy Eilertsen; Arild Nesbakken; Raquel Seruca; Ivar P Gladhaug; Espen Thiis-Evensen; Torleiv O Rognum; Kirsten Muri Boberg; Guro E Lind Journal: Int J Cancer Date: 2014-06-28 Impact factor: 7.396
Authors: Blanca L Valle; Sebastian Rodriguez-Torres; Elisabetta Kuhn; Teresa Díaz-Montes; Edgardo Parrilla-Castellar; Fahcina P Lawson; Oluwasina Folawiyo; Carmen Ili-Gangas; Priscilla Brebi-Mieville; James R Eshleman; James Herman; Ie-Ming Shih; David Sidransky; Rafael Guerrero-Preston Journal: Cancer Prev Res (Phila) Date: 2020-06-24